1、Click here or press enter for the accessibility optimised versionCell&GeneTherapies CI PerspectivePaul DSouza-Bento and Alex BourClick here or press enter for the accessibility optimised versionKey Takeawaysfor CI TeamsKey Takeaways for CI TeamsThe landscape for cell and gene therapies has been

2、evolving over the past few yearswith a rise in available treatments for rare and life-threatening diseases in the lastyear alone.This is despite generally high costs of R&D and manufacturing,coupledwith the infancy of scientific understanding compared to other areas of science.Despite the increa

3、sing volume of gene therapy assets targeting hematological malignancies,significantmarket potential exists,driven by the complexities in treatment-related adverse events among approvedproducts opportunities for further differentiation thus exists for novel therapies.As cell and gene therapies move i

4、nto indications with larger disease burdens,manufacturers will have amyriad of factors to consider,including the holistic value of a potentially curative therapy on already strainedhealthcare systems,payer price-sensitivity,and a potentially depleting patient population.The curative potential of cel

5、l and gene therapies presents paradigm-shifting opportunities and challenges tothe biopharma industry,requiring CI teams with deep therapy area knowledge and access to robustsecondary and primary insights to support critical strategic decision-making at key inflection points.Click here or press ente

6、r for the accessibility optimised versionGene TherapyLandscapeGene Therapy LandscapeSince 2004,32 gene therapies,including genetically modified cell therapies,have been registered covering oncology indications,including non-Hodgkinslymphoma(NHL),acute lymphocytic leukaemia(ALL),and chronic lymphocyt